Short Interest in ASP Isotopes Inc. (NASDAQ:ASPI) Increases By 86.8%

ASP Isotopes Inc. (NASDAQ:ASPI) was the recipient of a large increase in short interest during the month of June. As of June 30th, there was short interest totalling 2,840,000 shares, an increase of 86.8% from the June 15th total of 1,520,000 shares. Based on an average trading volume of 947,200 shares, the days-to-cover ratio is currently 3.0 days. Currently, 10.3% of the company’s shares are sold short.

ASP Isotopes Stock Down 2.5 %

ASP Isotopes stock traded down $0.09 during trading hours on Friday, reaching $3.47. The stock had a trading volume of 4,886,518 shares, compared to its average volume of 1,186,259. The company has a debt-to-equity ratio of 1.70, a quick ratio of 3.57 and a current ratio of 3.57. The business’s 50 day moving average price is $3.98 and its 200-day moving average price is $3.42. ASP Isotopes has a 52 week low of $0.58 and a 52 week high of $5.67.

ASP Isotopes (NASDAQ:ASPI) last posted its quarterly earnings data on Wednesday, May 15th. The company reported ($0.16) earnings per share (EPS) for the quarter. The firm had revenue of $0.84 million for the quarter. As a group, equities analysts anticipate that ASP Isotopes will post -0.11 EPS for the current fiscal year.

Analysts Set New Price Targets

Separately, HC Wainwright lifted their price objective on shares of ASP Isotopes from $5.25 to $5.50 and gave the company a “buy” rating in a research report on Wednesday, April 17th.

Insider Transactions at ASP Isotopes

In other news, Director Robert John Andrew Ryan purchased 9,500 shares of the stock in a transaction that occurred on Thursday, April 25th. The stock was bought at an average cost of $3.42 per share, for a total transaction of $32,490.00. Following the acquisition, the director now directly owns 546,555 shares of the company’s stock, valued at approximately $1,869,218.10. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other news, major shareholder Ak Jensen Investment Managemen purchased 70,000 shares of the company’s stock in a transaction that occurred on Monday, July 8th. The shares were bought at an average price of $3.05 per share, for a total transaction of $213,500.00. Following the purchase, the insider now directly owns 6,586,874 shares in the company, valued at approximately $20,089,965.70. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, Director Robert John Andrew Ryan purchased 9,500 shares of the company’s stock in a transaction dated Thursday, April 25th. The shares were bought at an average cost of $3.42 per share, for a total transaction of $32,490.00. Following the acquisition, the director now owns 546,555 shares in the company, valued at $1,869,218.10. The disclosure for this purchase can be found here. In the last ninety days, insiders acquired 145,662 shares of company stock worth $470,078. 26.30% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in ASPI. HTLF Bank acquired a new stake in shares of ASP Isotopes during the 4th quarter worth about $141,000. Rathbones Group PLC purchased a new position in shares of ASP Isotopes in the 4th quarter valued at about $272,000. Vanguard Group Inc. raised its position in shares of ASP Isotopes by 479.1% during the 1st quarter. Vanguard Group Inc. now owns 1,021,019 shares of the company’s stock worth $4,217,000 after acquiring an additional 844,705 shares in the last quarter. Finally, Virtu Financial LLC raised its position in shares of ASP Isotopes by 477.0% during the 1st quarter. Virtu Financial LLC now owns 83,677 shares of the company’s stock worth $346,000 after acquiring an additional 69,176 shares in the last quarter. Hedge funds and other institutional investors own 16.80% of the company’s stock.

ASP Isotopes Company Profile

ASP Isotopes Inc, a development stage advanced materials company, focuses on the production, distribution, marketing, and sale of isotopes. It engages in the production and commercialization of Molybdenum-100, a non-radioactive isotope for the medical industry; Carbon-14; and Silicon-28. The company is also developing Quantum Enrichment technology to produce Ytterbium-176, Nickel-64, Lithium 6, Lithium7, and Uranium-235.